Anaplastic thyroid carcinoma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:142C73
Who is this for?
Show terms as
1FDA treatments18Active trials71Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Anaplastic thyroid carcinoma (ATC), also called undifferentiated thyroid cancer, is one of the rarest and most aggressive forms of cancer. It starts in the thyroid gland, a butterfly-shaped gland in the front of your neck that controls your metabolism and many body functions. Unlike other thyroid cancers that grow slowly, anaplastic thyroid carcinoma grows very fast and can spread quickly to nearby structures in the neck and to other parts of the body such as the lungs, bones, and brain. The most common symptom is a rapidly growing lump or mass in the neck that can feel hard and fixed in place. As the tumor grows, it can press on the windpipe and food pipe, making it hard to breathe or swallow. Some people also experience a hoarse voice, pain in the neck, or swollen lymph nodes. Because the tumor grows so quickly, symptoms often develop over just a few weeks. Treatment usually involves a combination of surgery, radiation therapy, and chemotherapy, though the cancer is often too advanced for surgery by the time it is found. Newer targeted therapies, including drugs that target specific gene changes in the tumor, have shown promise and are changing how this disease is treated. Despite these advances, anaplastic thyroid carcinoma remains very difficult to treat, and finding it as early as possible gives the best chance of a better outcome.

Key symptoms:

Rapidly growing lump or swelling in the front of the neckDifficulty breathing or shortness of breathDifficulty swallowing food or liquidsHoarse or changed voicePain or pressure in the neckSwollen lymph nodes in the neckCoughing, sometimes with bloodFeeling of tightness in the throatUnexplained weight lossFatigue and general weaknessFever in some cases

Clinical phenotype terms (23)— hover any for plain English
Anaplastic thyroid carcinomaHP:0011779Broad neckHP:0000475Nodular goiterHP:0005994Vocal cord paralysisHP:0001605Upper airway obstructionHP:0002781Laryngotracheal stenosisHP:0004894Neoplasm of the lungHP:0100526Neoplasm of the skeletal systemHP:0010622Abnormal skeletal muscle morphologyHP:0011805
Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Late onset

Begins later in life, typically after age 50

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Sep 2026A Multi-Center Single-Arm Phase 2 Trial Of Zanzalintinib In Combination With Cemiplimab In BRAF Wild-Type Anaplastic Thyroid Cancer: The ZEPHYR Trial

M.D. Anderson Cancer Center — PHASE2

TrialNOT YET RECRUITING
Jun 2026Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial

Radboud University Medical Center — PHASE1

TrialNOT YET RECRUITING
Jan 2026[177Lu]Lu-AKIR001 First-in-human Study

Karolinska University Hospital — EARLY_PHASE1

TrialRECRUITING
Oct 2025IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

Hospices Civils de Lyon — PHASE2

TrialRECRUITING
Sep 2025Taiwanese Anaplastic Thyroid Cancer Registry

National Health Research Institutes, Taiwan

TrialNOT YET RECRUITING
Jun 2025XL092 and Cemiplimab in BRAF WT Thyroid Cancer

UNC Lineberger Comprehensive Cancer Center — PHASE1

TrialRECRUITING
Feb 2025Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC

Zhejiang Provincial People's Hospital — PHASE1, PHASE2

TrialNOT YET RECRUITING
Dec 2024Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer

West China Hospital — PHASE2

TrialNOT YET RECRUITING
Sep 2024Sacituzumab govitEcan in THYroid Cancers

Grupo Espanol de Tumores Neuroendocrinos — PHASE2

TrialRECRUITING
May 2024Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences

Power Life Sciences Inc.

TrialNOT YET RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

Tafinlar Capsules and Mekinist Tablets

dabrafenib and trametinib· Novartis Pharmaceuticals Corporation
indicated, in combination with dabrafenib and trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfa

indicated, in combination with dabrafenib and trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options

Clinical Trials

18 recruitingView all trials with filters →
Phase 213 trials
Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
Phase 2
Active
PI: Eric Sherman, MD (Memorial Sloan Kettering Cancer Center) · Sites: Basking Ridge, New Jersey; Middletown, New Jersey +5 more · Age: 1899 yrs
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Phase 2
Actively Recruiting
PI: Alan Ho, MD, PhD (Memorial Sloan Kettering Cancer Center) · Sites: Basking Ridge, New Jersey; Middletown, New Jersey +5 more · Age: 1899 yrs
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
Phase 2
Active
PI: Amir A Jazaeri (M.D. Anderson Cancer Center) · Sites: Houston, Texas · Age: 1670 yrs
Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer
Phase 2
Active
PI: Jochen H Lorch, M.D. (Northwestern University) · Sites: Chicago, Illinois; Houston, Texas · Age: 1899 yrs
NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)
Phase 2
Actively Recruiting
PI: Ellen Kapiteijn, MD, PhD (Leiden University Medical Center) · Sites: Leiden, South Holland · Age: 1899 yrs
Sacituzumab govitEcan in THYroid Cancers
Phase 2
Actively Recruiting
PI: Alejandro García-Alvarez, M.D.; Ph.D. (Hospital Universitario Vall d´Hebron) · Sites: Barcelona; Ferrol +9 more · Age: 1899 yrs
Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
Phase 2
Active
PI: Makoto Tahara, MD, PhD (National Cancer Center Hospital East) · Sites: Nagoya, Aichi-ken; Kashiwa, Chiba +8 more · Age: 2099 yrs
Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
Phase 2
Active
PI: Mark Zafereo (M.D. Anderson Cancer Center) · Sites: Stanford, California; Ann Arbor, Michigan +4 more · Age: 1899 yrs
Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Phase 2
Active
PI: Saad A Khan (Stanford University) · Sites: Palo Alto, California · Age: 1899 yrs
Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
Phase 2
Actively Recruiting
· Sites: Saint Petersburg · Age: 1899 yrs
IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
Phase 2
Actively Recruiting
· Sites: Angers; Bordeaux +13 more · Age: 1899 yrs
Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy
Phase 2
Actively Recruiting
· Sites: Saint Petersburg · Age: 1899 yrs
Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
Phase 2
Active
PI: Maria E Cabanillas (M.D. Anderson Cancer Center) · Sites: Houston, Texas · Age: 1899 yrs
Phase 13 trials
Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer
Phase 1
Active
PI: Sonal Gupta, MD PhD (AffyImmune Therapeutics, Inc.) · Sites: Duarte, California; Chicago, Illinois +2 more · Age: 1899 yrs
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
Phase 1
Actively Recruiting
PI: Siddharth Sheth, DO MPH (UNC Lineberger Comprehensive Cancer Center) · Sites: Boston, Massachusetts; Chapel Hill, North Carolina · Age: 1899 yrs
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
Phase 1
Actively Recruiting
PI: Sasan Fazeli, MD (City of Hope Medical Center) · Sites: Duarte, California; Columbus, Ohio +1 more · Age: 1899 yrs
Other1 trial
GETNE Registration of Thyroid Cancer
Actively Recruiting
PI: Jorge Hernando Cubero, M.D. (Hospital Universitari Vall d'Hebron, Barcelona) · Sites: Barcelona · Age: 1899 yrs

Specialists

Showing 25 of 71View all specialists →
EM
Eric Sherman, MD
Specialist
PI on 2 active trials
KM
Kartik Seghal, MD
Specialist
PI on 2 active trials
CM
Charles Hsu, MD
Specialist
PI on 1 active trial
ZT
Zhuo Tan
Specialist
4 Anaplastic thyroid carcinoma publications
CZ
Chuanming Zheng
Specialist
2 Anaplastic thyroid carcinoma publications
PH
Ping Huang
OAKLAND GARDENS, NY
Specialist
3 Anaplastic thyroid carcinoma publications
LB
Lisha Bao
Specialist
2 Anaplastic thyroid carcinoma publications
MG
Minghua Ge
Specialist
5 Anaplastic thyroid carcinoma publications
XL
Xixuan Lu
Specialist
2 Anaplastic thyroid carcinoma publications
JC
Jinming Chen
Specialist
2 Anaplastic thyroid carcinoma publications
LJ
Liehao Jiang
Specialist
2 Anaplastic thyroid carcinoma publications
MW
Michelle D Williams
Specialist
2 Anaplastic thyroid carcinoma publications
FS
Feifeng Song
Specialist
2 Anaplastic thyroid carcinoma publications
YL
Yujia Liu
SAN DIEGO, CA
Specialist
2 Anaplastic thyroid carcinoma publications
ZP
Zongfu Pan
Specialist
4 Anaplastic thyroid carcinoma publications
TX
Tong Xu
IOWA CITY, IA
Specialist
2 Anaplastic thyroid carcinoma publications
JW
Jiafeng Wang
Specialist
3 Anaplastic thyroid carcinoma publications
YZ
Yiwen Zhang
Specialist
3 Anaplastic thyroid carcinoma publications
MS
Manisha Shah
Specialist
PI on 4 active trials177 Anaplastic thyroid carcinoma publications
EP
Ellen Kapiteijn, MD, PhD
Specialist
PI on 3 active trials
SP
Sandip P Patel
Birmingham, Alabama
Specialist

Rare Disease Specialist

PI on 1 active trial
NM
Naris Nilubol, M.D.
LONG ISLAND CITY, NY
Specialist
PI on 8 active trials
JM
James Gulley, M.D.
BETHESDA, MD
Specialist
PI on 3 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Anaplastic thyroid carcinoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Anaplastic thyroid carcinomaForum →

No community posts yet. Be the first to share your experience with Anaplastic thyroid carcinoma.

Start the conversation →

Latest news about Anaplastic thyroid carcinoma

Disease timeline:

New recruiting trial: Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

A new clinical trial is recruiting patients for Anaplastic thyroid carcinoma

New recruiting trial: Sacituzumab govitEcan in THYroid Cancers

A new clinical trial is recruiting patients for Anaplastic thyroid carcinoma

New recruiting trial: XL092 and Cemiplimab in BRAF WT Thyroid Cancer

A new clinical trial is recruiting patients for Anaplastic thyroid carcinoma

New recruiting trial: GETNE Registration of Thyroid Cancer

A new clinical trial is recruiting patients for Anaplastic thyroid carcinoma

New recruiting trial: Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

A new clinical trial is recruiting patients for Anaplastic thyroid carcinoma

New recruiting trial: A Study of Avutometinib and Defactinib in People With Thyroid Cancer

A new clinical trial is recruiting patients for Anaplastic thyroid carcinoma

New recruiting trial: NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)

A new clinical trial is recruiting patients for Anaplastic thyroid carcinoma

New recruiting trial: Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer

A new clinical trial is recruiting patients for Anaplastic thyroid carcinoma

New recruiting trial: IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

A new clinical trial is recruiting patients for Anaplastic thyroid carcinoma

New recruiting trial: Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy

A new clinical trial is recruiting patients for Anaplastic thyroid carcinoma

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Has my tumor been tested for the BRAF V600E mutation and other gene changes, and what did those results show?,Am I a candidate for surgery, and if not, what is the plan for local control of the tumor?,Are there any clinical trials I might be eligible for?,What is the goal of treatment — to try to cure the cancer, slow it down, or focus on comfort?,How will we manage symptoms like difficulty breathing and swallowing as the disease progresses?,When should I involve a palliative care team, and what can they offer me?,What support resources are available for me and my family during this time?

Common questions about Anaplastic thyroid carcinoma

What is Anaplastic thyroid carcinoma?

Anaplastic thyroid carcinoma (ATC), also called undifferentiated thyroid cancer, is one of the rarest and most aggressive forms of cancer. It starts in the thyroid gland, a butterfly-shaped gland in the front of your neck that controls your metabolism and many body functions. Unlike other thyroid cancers that grow slowly, anaplastic thyroid carcinoma grows very fast and can spread quickly to nearby structures in the neck and to other parts of the body such as the lungs, bones, and brain. The most common symptom is a rapidly growing lump or mass in the neck that can feel hard and fixed in plac

How is Anaplastic thyroid carcinoma inherited?

Anaplastic thyroid carcinoma follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Anaplastic thyroid carcinoma typically begin?

Typical onset of Anaplastic thyroid carcinoma is late onset. Age of onset can vary across affected individuals.

Are there clinical trials for Anaplastic thyroid carcinoma?

Yes — 18 recruiting clinical trials are currently listed for Anaplastic thyroid carcinoma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Anaplastic thyroid carcinoma?

25 specialists and care centers treating Anaplastic thyroid carcinoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.